Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

534

Participants

Timeline

Start Date

November 30, 2002

Study Completion Date

July 31, 2005

Conditions
Coronary Heart Disease
Interventions
DRUG

Pactimibe, CS-505

Trial Locations (46)

Unknown

Birmingham

Huntsville

Mobile

Phoenix

Los Angeles

San Diego

Fort Collins

Bridgeport

Newark

Clearwater

Gainsville

Hudson

Jacksonville

Melbourne

Miami

Pensacola

Port Charlotte

Sarasota

Tallahassee

Tampa

Atlanta

Springfield

Louisville

Baltimore

Springfield

Grand Rapids

Kalamazoo

Duluth

Minneapolis

Kansas City

Lincoln

New York

Rochester

Troy

Charlotte

Greenville

High Point

Winston-Salem

Akron

Cleveland

Elyria

Mansfield

Oklahoma City

Doylestown

Memphis

San Antonio

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY